The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen.
Carmen Joseph Allegra
Consultant or Advisory Role - Sanofi ; Sanofi
Radek Lakomy
No relevant relationships to disclose
Josep Tabernero
Consultant or Advisory Role - Regeneron; Regeneron; Roche; Roche; Sanofi ; Sanofi
Jana Prausová
No relevant relationships to disclose
Paul Ruff
Honoraria - Amgen; Merck KGaA; Pfizer; Roche; Sanofi
Research Funding - Amgen; Merck KGaA; Pfizer; Sanofi
Other Remuneration - Amgen; Pfizer; Roche
Guy Van Hazel
No relevant relationships to disclose
Vladimir Mikhailovich Moiseyenko
No relevant relationships to disclose
David R Ferry
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Joseph J McKendrick
No relevant relationships to disclose
Eric Van Cutsem
Research Funding - Sanofi ; Sanofi